Michael, MR, Wieske, L, Allen, JA, Lunn, MP, Doppler, K, Tan, CY, Koike, H, Markvardsen, LK, Kapoor, M, Hsieh, ST, Nobile-Orazio, E, Jacobs, BC, Rajabally, YA, Basta, I, Ripellino, P, Querol, L, Eftimov, F. Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy. BMC Neurology. 2024; 24(1)DOI:10.1186/s12883-024-03903-w. PMID:39455929. IF:2.200(Q3/6D).

Monceau, A, Nath, RG, Suárez-Calvet, X, Musumeci, O, Toscano, A, Kierdaszuk, B, Kostera-Pruszczyk, A, Domínguez-González, C, Hernández-Lain, A, Paradas, C, Rivas, E, Papadimas, G, Papadopoulos, C, Chrysanthou-Piterou, M, Gallardo, E, Olivé, M, Lilleker, J, Roberts, ME, Marchese, D, Lunazzi, G, Heyn, H, Fernández-Simón, E, Villalobos, E, Clark, J, Katsikis, P, Collins, C, Mehra, P, Laidler, Z, Vincent, A, Tasca, G, Marini-Bettolo, C, Guglieri, M, Straub, V, Raben, N, Díaz-Manera, J. Decoding the muscle transcriptome of patients with late-onset Pompe disease reveals markers of disease progression. BRAIN. 2024; DOI:10.1093/brain/awae249. PMID:39045638. IF:11.700(Q1/1D).

Saposnik, G, Monreal, E, Medrano, N, García-Domínguez, JM, Querol, L, Meca-Lallana, JE, Landete, L, Salas, E, Meca-Lallana, V, García-Arcelay, E, Agüera-Morales, E, Martínez-Yélamos, S, Gómez-Ballesteros, R, Maurino, J, Villar, LM, Caminero, AB. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 2024; 90DOI:10.1016/j.msard.2024.105838. PMID:39216454. IF:2.900(Q2/4D).

Allen, JA, Lin, J, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Chang, T, Lipowska, M, Lowe, M, Lauria, G, Querol, L, Simu, MA, Suresh, N, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA, van Doorn, PA. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. LANCET NEUROLOGY. 2024; 23(10)DOI:10.1016/S1474-4422(24)00309-0. PMID:39304241. IF:45.500(Q1/1D).